LL-37 Antibody (B-T37) [Allophycocyanin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-18120APC
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry
Label
Allophycocyanin (Excitation = 620-650 nm, Emission = 660-670 nm)
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # B-T37
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Human antimicrobial peptide LL-37. Hybridoma: Myeloma X63/AG.8653 x Balb/c node cells
Specificity
Recognizes both natural and recombinant human LL-37
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Applications for LL-37 Antibody (B-T37) [Allophycocyanin]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: LL-37
Alternate Names
18 kDa cationic antimicrobial protein, Antibacterial peptide FALL-39, CAP18, CAP-18, cathelicidin antimicrobial peptide, CRAMP, epididymis secretory sperm binding protein, FALL39, FALL-39, FALL-39 peptide antibiotic, hCAP-181, HSD26, LL37
Gene Symbol
CAMP
Additional LL-37 Products
Product Documents for LL-37 Antibody (B-T37) [Allophycocyanin]
Product Specific Notices for LL-37 Antibody (B-T37) [Allophycocyanin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...